Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an in...
KemPharmÂŽ is a clinical-stage specialty pharmaceutical company engaged in the dis...
KemPharmÂŽ is a clinical-stage specialty pharma...
Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...
Nemucore Medical Innovations is here to bring y...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...
Heat Biologics a biopharmaceutical company that...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Join the National Investor Network and get the latest information with your interests in mind.